Cyclophosphamide monotherapy in children with Burkitt lymphoma: A study from the French–African Pediatric Oncology Group (GFAOP)

Abstract

A prospective multicentric study on BL was feasible in very low-income countries. CPM can be recommended in stage 1-2 because of optimal cost/benefit ratio. However, more intensive strategies, still adapted to socio-economic conditions, are required for advanced stages 3 and 4.